MedPage Today (3/22, Monaco) reported, “Concomitant use of selective serotonin reuptake inhibitors (SSRIs) and oral anticoagulants (OACs) in patients with atrial fibrillation was tied to an increased risk of major bleeding compared with OAC use alone, a case-control study suggested.”
This “population-based study from the U.K. showed that taking an SSRI and OAC (both direct OACs and vitamin K antagonists [VKAs]) together was associated with a 33% increased risk of major bleeding compared with OACs alone.” The data indicated that “compared with use of OACs alone, concomitant use of SSRIs plus OACs was linked to a significantly higher risk for several specific types of major bleeding.”
The findings were published in JAMA Network Open.
Related Links:
— MedPage Today (requires login and subscription)